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Stress response pathways are critical for cellular homeostasis, promoting survival through
adaptive changes in gene expression and metabolism. They play key roles in numerous
diseases and are implicated in cancer progression and chemoresistance. However, the
underlying mechanisms are only poorly understood. We have employed a multi-omics
approach to monitor changes to gene expression after induction of a stress response path-
way, the unfolded protein response (UPR), probing in parallel the transcriptome, the pro-
teome, and changes to translation. Stringent filtering reveals the induction of 267 genes,
many of which have not previously been implicated in stress response pathways. We
experimentally demonstrate that UPR‐mediated translational control induces the expression
of enzymes involved in a pathway that diverts intermediate metabolites from glycolysis to
fuel mitochondrial one‐carbon metabolism. Concomitantly, the cells become resistant to the
folate-based antimetabolites Methotrexate and Pemetrexed, establishing a direct link
between UPR‐driven changes to gene expression and resistance to pharmacological
treatment.
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Tumor cells can escape apoptotic cell death, and survive andproliferate in hostile environments often characterized by alack of nutrients and oxygen. For this, cancer cells exploit
intrinsic adaptive mechanisms and stress response pathways such
as the endoplasmic reticulum (ER) unfolded protein response
(UPR). The UPR is triggered by the accumulation of unfolded or
misfolded proteins in the ER and it aims at reinstating cellular
homeostasis, or, if that fails, at triggering of apoptosis. It is of
clinical importance and has key roles in a variety of disorders,
including metabolic diseases, neurodegenerative disorders, and
inflammatory processes1–5. Moreover, the UPR is broadly
implicated in cancer progression and malignancy, survival and
proliferation of cancer cells, and their resistance to pharmacolo-
gical treatment6–13. In particular, the latter is a major predictor of
mortality in cancer patients.
Given the central role of the UPR in clinically important cell
fate decisions, it has emerged as an attractive target for ther-
apeutic intervention with the aim to tilt the balance of protective
effects versus apoptosis for the benefit of patients14–22. Despite its
clinical relevance, it is still only poorly understood how the UPR
contributes to chemoresistance of cancer cells and a better
understanding of the underlying mechanisms and pathways is
urgently required to improve the therapeutic outcome.
In general, the UPR utilizes three main branches to sense
perturbations in ER homeostasis and to trigger the appropriate
cellular responses23. These depend on three proteins that span the
membrane of the ER to probe its status: inositol-requiring
enzyme-1 alpha (IRE1α, aka ERN1), activating transcription
factor 6 (ATF6), and PKR-like endoplasmic reticulum kinase
(PERK, aka EIF2AK3). The first two proteins with their respective
signal transduction pathways mainly exert their function via
transcriptional reprogramming, in contrast PERK controls cel-
lular translation through phosphorylation of eukaryotic transla-
tion initiation factor 2 alpha (EIF2S1)24.
To gain a comprehensive and systems-wide understanding of
the UPR, we have pursued a multi-omics approach that, upon
chemical induction of the UPR with two different compounds,
monitors in parallel several parameters in the astrocytoma cell
line LN-308. Changes to the cellular transcriptome (by high
throughput sequencing) and proteome (by shotgun and targeted
proteomics) as well as altered translation status (by ribosome
profiling) were measured after different time points of treatment.
Integration of the datasets reveals the induction of 267 genes (the
UPR regulon), including numerous cancer-relevant factors and
metabolic enzymes. We detect evidence for a UPR-dependent
metabolic reprogramming that diverts metabolites from glycolysis
to mitochondrial one-carbon (1C) metabolism. This renders the
cells insensitive to treatment with the FDA-approved folate-based
antimetabolites Methotrexate and Pemetrexed, establishing a
direct link between UPR-driven changes to gene expression and
resistance to pharmacological treatment.
Results and discussion
Induction of the UPR in LN-308 cells. To trigger the UPR in the
astrocytoma-derived cell line LN-308, we used two different
compounds: the nucleoside antibiotic and N-glycosylation inhi-
bitor tunicamycin (TM) and the SERCA inhibitor thapsigargin
(TH)25,26. We determined concentrations for both compounds
that result in the activation of key factors of the UPR and/or their
effects on downstream targets while not causing a full replicative
arrest of the cells (200 nM Thapsigargin or 2.5 µg/ml Tunica-
mycin). Treatment of LN-308 cells under these conditions rapidly
induces IREα-mediated, cytoplasmic processing of X-box Binding
Protein 1 (XBP1) mRNA, which can be detected by RT-PCR after
2 h of treatment (Supplementary Fig. 1A). This results in the
production of functional, full-length XBP1s protein (Supple-
mentary Fig. 1B), which can only be translated from the fully
processed mRNA. The ratio of spliced versus unspliced XBP1
mRNA oscillates over the time-course of the treatment which is,
to some extent, also reflected in changes to the XBP1s protein
level, underscoring the dynamic and adaptive nature of the UPR.
Another rapid response to ER stress is phosphorylation and
activation of PERK, which results in a slightly reduced gel
mobility27 that can be detected already after 1 h of treatment and
which becomes more pronounced at later times (Supplementary
Fig. 1B). Concomitantly, increased phosphorylation of the PERK
downstream target EIF2S1 on Ser51 can be observed (Supple-
mentary Fig. 1B). This in turn promotes activating transcription
factor 4 (ATF4) protein production by a translation re-initiation
mechanism that is sensitive to EIF2S1 phosphorylation28,29.
ATF4 protein levels are elevated at 2 h and peak at 4–6 h, how-
ever, decreased protein levels are observed at later time points
(e.g. after 24 h of treatment). In contrast, a different kinetic can be
observed for the induction of the ER chaperone heat shock
protein family A (Hsp70) member 5 (HSPA5 aka BiP): an
increase in abundance of the protein can be detected only after
4–6 h, however, the protein abundance increases continuously
during the treatment, resulting in a strong accumulation of
HSPA5 protein after 24 h (Supplementary Fig. 1B).
Staged sampling of the UPR. To gain a more comprehensive
insight into the adaptive response initiated by ER stress, we
expanded our analyses and employed a multi-omics approach to
probe cellular translation (by ribosome profiling), the tran-
scriptome, and the proteome at different time points. As changes
to the translation status of the cell are rapid (e.g. ATF4 induction
after phosphorylation of EIF2S1, Supplementary Fig. 1B), we
performed ribosome profiling at early time points, after 2 and 6 h
of treatment (Fig. 1a). In parallel, we assayed the cellular tran-
scriptome as a reference for the determination of translation
efficiencies of different RNA species. In addition, the transcrip-
tional profiling data yield insight into (early) RNA processing
events (such a XBP1 mRNA splicing, Supplementary Fig. 1A), but
also show UPR-dependent transcriptional reprogramming
towards later time points when changes to the steady state levels
of an increasing number of mRNAs become detectable. Finally,
proteomic changes were analyzed at 6 h and later time points (16
h and 24 h) to cover early translational responses but also to gain
insight into adaptive changes to continuously ongoing and
developing chronic ER stress—a situation frequently encountered
in disease.
Our findings attest to the validity of this approach: (1) our
analyses reveal significant and wide-spread changes of the cellular
transcriptome and altered translation after 2 and 6 h of treatment
(Figs. 1, 2, Supplementary Figs. 2, 3)—in contrast, at 6 h the
cellular proteome remains almost unchanged and adaptive
changes to the steady state levels of numerous proteins become
apparent only at later stages (Fig. 3), and (2) as expected, for most
responsive genes transcriptomic changes precede changes in
protein abundance. This is also reflected by the finding that
transcriptomic changes after 6 h enrich for the same GO-terms as
proteomic changes after 16 h. However, no such correlation can
be found when comparing the 6 h time points.
Differential gene expression during the UPR. To experimentally
assess UPR-mediated transcriptional reprogramming, we ana-
lyzed RNA expression by high throughput sequencing after 2 and
6 h of treatment with either TM or TH (Supplementary Data 2).
Both compounds cause significant changes to the cellular tran-
scriptome after 2 h of treatment.
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The steady state levels of ∼700 protein-coding RNAs respond
to inhibition of N-glycosylation by TM for 2 h (315 with
increased abundance, 381 with decreased abundance, Supple-
mentary Fig. 2A), and after 6 h of treatment we find ∼1500
mRNAs that change abundance (793 with increased abundance,
794 with decreased abundance). Importantly, there is only a
limited overlap between both time points (R2= 0.32, Supple-
mentary Fig. 2B), and only few transcripts are upregulated or
downregulated at both 2 and 6 h of TM treatment (110 up and
171 down, Supplementary Fig. 2C) indicating that the cellular
response to TM treatment is dynamic and changes from 2 to 6 h
of treatment.
Exposure to TH induces an even greater change to the
cellular transcriptome: after 2 and 6 h, we detect significant
changes to the abundance of 1442 and 1438 mRNAs,
respectively (Supplementary Fig. 2A). The changes to the
cellular transcriptome at 2 and 6 h correlate better (R2= 0.71,
Supplementary Fig. 2B) than observed for the treatment with
TM. This is also reflected in the much higher number of RNAs
that show a similar regulation after 2 and 6 h of TH treatment:
∼30% of the transcripts that are upregulated after 2 h also show
an increased abundance after 6 h (Supplementary Fig. 2C). The
overlap is even more pronounced for the transcripts that exhibit
reduced steady state levels upon treatment (∼43% of the
transcripts that show reduced levels at 2 h of treatment are still
downregulated after 6 h of treatment).
UPR-mediated translational reprogramming. Phosphorylation
of EIF2S1 by PERK upon accumulation of unfolded proteins in
the ER rapidly attenuates translation of the vast majority of
messenger RNAs. In agreement with this, we observe an ~34%
reduction of translation after 6 h of TM treatment as evidenced by
metabolic incorporation of 35S-labeled methionine and a decrease
of polysomal complexes (Supplementary Fig. 3). However,
translation of the major coding region of a group of transcripts is
insensitive to EIF2S1 phosphorylation and increased translation
can be observed under stress conditions. This is thought to mostly
depend on upstream open reading frames (uORFs) and often
involves translation re-initiation28.
To better understand UPR-mediated control of translation
during ER stress, we employed ribosomal profiling, a quantitative
and transcriptome-wide systems analysis of translation. After
limited ribonucleolytic digestion, mRNA-derived ribosome-pro-
tected fragments (RPFs) are subjected to high throughput
sequencing, revealing with high resolution the positions of
(translating) ribosomes on mRNAs.
Our analyses reveal wide-spread changes to the abundance of
RPFs upon treatment with either TM or TH (Supplementary
Data 3). In agreement with attenuated translation due to
phosphorylation of EIF2S1, we find in particular at early time
points (2 h after induction of the UPR) an overall reduction of
RPFs from numerous loci, (TM 171, TH 386). In contrast, under
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Fig. 1 A multi-omics approach to analyze the UPR. a Schematic depiction of the staged sampling scheme employed in this study. b Comparison of TM-
and TH-induced changes to RNA expression levels highly enriches for factors involved in the UPR. Plotted are directional P-values of differentially
expressed protein-coding genes after 2 h of treatment. Enrichment scores and P-values for the GO-terms PERK-mediated UPR (GO:0036499) and
regulation of response to ER stress (GO:1900101) are given for genes that are upregulated after (1) inhibition of N-glycosylation (by TM treatment, area
shaded in light gray) (2) after inhibition of the SERCA (by TH treatment, area shaded in dark gray) and (3) upregulated in both treatments (striated area). c
Comparison of differences in mRNA abundance of protein-coding genes induced by treatment with TM or TH for 2 h (left panel) and 6 h (right panel) (see
also Supplementary Fig. 2 and Supplementary Data 2). d Comparison of TM- and TH-induced changes to ribosome-protected fragment counts after 2 h
(left panel) and 6 h of treatment (right panel) (see also Supplementary Fig. 4 and Supplementary Data 3). In c, d log2-fold changes of mean values are
plotted. Two criteria were used to identify regulated genes: (a) fold-change in the 5% (downregulation) and 95% (upregulation) quantiles and (b) a P-
value threshold (<0.05). Color coding b–d—gray dots: no significant change in either treatment; green dots: significantly upregulated or downregulated in
only one treatment or inversely regulated upon TM and TH treatment; yellow dots: statistically significant regulation in the same direction in both
treatments; red dots: known factors of the UPR. Select factors involved in the UPR are marked by arrows.
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RPFs (TM 74, TH 155) (Supplementary Fig. 4A). After 6 h of
continuous treatment, the effect is less pronounced and the
numbers of loci that yield significantly more RPFs or that
generate fewer reads are comparable. Again, we only detect a poor
correlation between the genes that are upregulated or down-
regulated upon treatment with TM or TH after 2 and 6 h
(Supplementary Fig. 4B) suggesting that ER stress-induced gene
regulation is highly dynamic.
Changes to the abundance of RPFs from a protein-coding locus
can be essentially caused by either, a change in mRNA
abundance, an altered translation rate, or both. As such, ribosome
profiling, when not corrected for changes in RNA abundance,
monitors both transcriptome changes and regulated translation.
After 2 h of TM treatment, the detected changes to RNA
abundance and RPFs exhibit little correlation (R2= 0.12, Fig. 2).
This suggests that either regulation of translation and transcrip-
tion affects different gene sets, or that effects on translation
dominate over mRNA abundance changes at this early time
point. In contrast, after 6 h a much higher correlation can be
observed between changes to RPF counts and RNA abundance
(R2= 0.7, Fig. 2). This indicates that after prolonged treatment
most changes to gene expression are driven by altered RNA
steady state levels instead of selective translation, which suggests
that at least at this time-point transcriptional regulation
dominates over translational control.
To get further insight into translational control under these
cellular stress conditions, we approximated mRNA translation
efficiency by the calculation of ribosome loading scores (RPF
counts normalized by RNA abundance). Changes to ribosome
loading of individual transcripts are indicative of changes to
translation rates as they reflect either an altered density of
translating ribosomes or, less frequently, ribosome stalling. In our
data, we observe an overall decrease in ribosome loading after
treatment (Fig. 2b and Supplementary Fig. 3B), which agrees with
an overall decrease of translation upon PERK-mediated phos-
phorylation of EIF2S1 at serine 51 that is initiated as an
immediate response to ER stress (Supplementary Fig. 1B). In
agreement with previous studies of translation rates under stress
conditions31,32, we find numerous transcripts that appear to resist
EIF2 phosphorylation and exhibit increased association with
ribosomes upon induction of the UPR (Fig. 2b). We also detect a
set of mRNAs that is hyper-sensitive to EIF2S1 phosphorylation
and which produces significantly fewer RPFs under stress
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Fig. 2 Global analysis of UPR-mediated translation regulation. a Comparison of differential RNA expression and changes to RPF abundance of protein-
coding RNAs after 2 h (left panel) or 6 h (right panel) of TM treatment. Loci with a P-value below threshold are depicted yellow, plotted are log2-fold
changes of mean values. b Analyses of ribosome loading scores of protein-coding RNAs after 2 h (left panel) and 6 h (right panel) of TM stimulation. Note
the overall reduction in ribosome loading (for reference the dashed line indicates no change in ribosome loading). RNAs that exhibit statistically significant
changes in ribosome loading are shown in yellow.
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Proteomic changes during the UPR. To globally assess the
steady state changes of the proteome, we performed shotgun MS
analyses at three different time points after treatment with either
TM or TH. We detect 4131 proteins with at least two peptides of
which ~50% (2136 proteins) exhibit significant abundance
changes in one of the experimental conditions (Supplementary
Data 4). Of these proteins, 309 exhibit an abundance change of
±2-fold the standard deviation (7% of the proteome). As pre-
dicted, changes to the proteome appear with a delay compared to
the changes observed for translation rates and RNA abundance.
In agreement with this, the abundance of only few proteins is
changed after 6 h of treatment (TM 40, TH 92), whereas the
number of regulated proteins increases at later time points (TM
102, TH 127 after 24 h, Fig. 3). Overall, more proteins are found
to be downregulated than upregulated, which is in good agree-
ment with the ribosome profiling data and indicative of a globally
reduced protein synthesis rate (Fig. 2). Again, we detect a limited
overlap between the proteins that change abundance after treat-
ment with either TH or TM (20% overlap for upregulated and
24% for downregulated genes, Fig. 3). Most of the proteins
involved in UPR-mediated stress signaling are not abundantly
expressed, hampering their detection by shotgun proteomics. We
previously established a targeted proteomics workflow to monitor
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Fig. 3 UPR-induced changes to the cellular proteome. a Time-resolved comparison of changes to protein abundance after TM treatment (left) or TH
treatment (right). b Comparison of TM and TH-induced changes to protein abundance after 6, 16, and 24 h of treatment. c Comparison of mean values of
protein abundance changes 6 h (top panel), 16 h (middle panel), and 24 h (bottom panel) after stimulation with either TH or TM. Data from shotgun
proteomics are color-coded as in Fig. 1. Additional data points from a targeted proteomics approach30 are shown as black dots. Select proteins involved in
the UPR are marked by arrows. (see also Supplementary Fig. 5 and Supplementary Data 4). Two criteria were used to filter for regulated genes: a fold-
change median ± 2 * standard deviation (as indicated by the dashed lines), and a P-value threshold (<0.05).
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the UPR (IRE1, PERK, ATF6, XBP1, GADD34, CHOP, ATF4,
and ATF3)30. Using this approach, we confirm a ∼30-fold
induction of ATF4 protein 6 h after treatment with either TM or
TH. Similarly, we detect a ∼60-fold increase in XBP1 and a ∼50-
fold increase in CHOP protein after induction of the UPR. This is
consistent with our analyses of translation rates, RNA-abundance
and protein levels by western blotting (Figs. 1–3, Supplementary
Fig. 1).
Co-regulation by TM and TH treatment. Importantly, pertur-
bations of calcium homeostasis (by treatment with TH) or pro-
tein glycosylation (by treatment with TM) also induce adaptive
cellular responses other than the UPR (side effects)25,26, resulting
in gene expression changes unrelated to accumulation of unfol-
ded proteins in the ER. As TM and TH interfere with very dif-
ferent cellular pathways, we expect on the one hand distinct,
cellular responses that differ between the two reagents. On the
other hand, we reasoned that adaptive changes to gene expression
that are shared between the two chemical treatments are very
likely driven by the UPR. Hence, filtering for gene expression
changes observed in both treatments would allow us to specifi-
cally enrich for UPR-mediated cellular responses (Fig. 1b).
Once triggered, the UPR exhibits a characteristic order of
events whose timing is largely independent of the nature of the
stimulus. Rather it is determined by the enzymatic properties of
the regulatory factors and the kinetics of the gene expression
program. This is illustrated by the fact that, despite being the
much stronger stimulus that results in much higher gene
expression changes, TH-induced and UPR-driven changes to
gene expression follow the same kinetics (and fluctuations) as the
UPR-driven response induced by TM (Supplementary Fig. 1). We
therefore independently analyzed changes to gene expression
(RNA abundance and ribosome profiling) after 2 and 6 h to
identify transcripts that are co-regulated in both treatment
regimens at the same time point (Fig. 1c, d, Supplementary
Figs. 2, 4, panels D, E).
As expected, the overall correlation between transcriptomic
changes in both treatments is not very high (R2= 0.46 after 2 h
and R2= 0.58 after 6 h of treatment, Fig. 1c and Supplementary
Fig. 2E), confirming that TH and TM trigger different and only
partially overlapping cellular responses. At the early time point,
after 2 h of treatment, only few mRNAs exhibit a similar
regulation in both treatment regimens (161 up, 109 down),
whereas at 6 h, a larger proportion of RNAs is co-regulated (454
up, 232 down) (Supplementary Fig. 2D).
Previously, it has been reported that in cultured mouse
embryonic fibroblasts (MEFs) the activation of IRE1 destabilizes
~120 different mRNAs through regulated IRE1-dependent decay
(RIDD). RIDD preferentially targets ER-localized RNAs and
initiates degradation by sequence-specific endonucleolytic clea-
vage, analogous to its role in XBP1 mRNA splicing33. In contrast
to the strong RIDD-mediated regulation observed in Droso-
phila34, in MEFs the steady state level changes were generally
smaller (log2-fold-change <2) and therefore challenging to
detect35. We find that treatment with TM or TH results in the
downregulation of largely distinct sets of mRNAs (∼10% co-
regulated transcripts after 2 h of treatment, ∼20% after 6 h,
Fig. 1c, Supplementary Fig. 2D, E) and after 2 or 6 h of treatment
only 109 and 232 transcripts are co-down regulated in both
treatments. Among these, we detect an enrichment of RNAs that
encode membrane proteins. Strikingly, we do not detect an
enrichment of previously identified RIDD target mRNAs among
these RNAs, although the effective removal of the critical intron
in the XBP1 mRNA indicates activation of IRE1α (Supplementary
Fig. 1A). This suggests that under the conditions tested here the
contribution of RIDD to RNA abundance changes is rather small
and the decay of RIDD target RNAs is difficult to detect.
For the transcripts that are increased in abundance upon TH or
TM treatment after 2 h, about 19% (161 protein-coding loci) are
detected in both treatment conditions; after 6 h, this fraction is
increased to ∼43% (454 protein-coding loci, Supplementary
Fig. 2D). We detect many mRNAs encoding proteins involved in
the UPR among the upregulated transcripts (Fig. 1c and
Supplementary Fig. 2E, highlighted in red), many of which are
co-regulated in both treatment regimens. In particular, under
almost all conditions tested, we detect upregulation of transcripts
that encode the major transducers of the UPR and their
prominent targets: PERK (EIF2AK3), IRE1α (ERN1), XBP1,
ATF6, ATF4, CHOP (DDIT3), and BiP (HSPA5) (Fig. 1c and
Supplementary Fig. 2E, marked with arrows). For a more
comprehensive analysis, we tested for the enrichment of GO-
terms in the subsets of transcripts with increased abundance after
2 h. When individually analyzing the TH or TM treatments, we
detect (among others) an enrichment of the GO-terms PERK-
mediated unfolded protein response (GO:36499) and regulation
of response to ER stress (GO:1900101) (Fig. 1b) (GO:36499: TM
∼44-fold, P-value: 2.17 × 10e−6; TH ∼18-fold, P-value: 1.1 × 10e
−2; GO:1900101: TM ∼8-fold, P-value: 1.15 × 10e−2; TH ∼6-
fold, P-value: 1.72 × 10e−4). When restricting the analysis to the
transcripts that are co-regulated in both treatments, both GO-
terms become even further enriched (more than 75-fold and 14-
fold, respectively). Comparable results are obtained when gene
expression changes after 6 h of treatment are analyzed.
Similar to transcriptional regulation, the analysis of ribosome-
protected fragments indicates that treatment with TM or TH
triggers largely different cellular responses (Fig. 1d, Supplemen-
tary Fig. 4D, E). Although after 2 h of treatment, the number of
co-regulated genes is rather low (14 up, 41 down, Fig. 1d and
Supplementary Fig. 3), a significant number of co-upregulated
genes can be detected after 6 h. Among the 257 genes that exhibit
a significant increase of ribosome-protected fragments, we again
detect a strong enrichment of factors that are functionally
connected to the UPR as reflected by the enrichment of UPR-
associated GO-terms.
In sum, this validates our correlative multi-omics approach and
demonstrates that stringent filtering allows to further enrich the
UPR-driven changes.
The UPR regulon. We find that adaptive changes to gene
expression that are shared between treatment with TM or TH are
strongly enriched for known UPR-mediated gene regulation. This
suggests that other genes that exhibit a similar expression sig-
nature, also are likely under the control of the same pathway, the
UPR. By analyzing changes to the transcriptome, the proteome,
and to ribosome occupancy that are found in both treatments, we
can now define the UPR regulon.
Here we focus on genes that encode proteins that show
increased synthesis after treatment, suggesting a function in the
ER stress response pathway (Supplementary Data 1). Genes that
are induced on the level of the RNA (as judged by differential
expression after treatment) can be considered to be part of the
UPR regulon sensu stricto. However, if the increase in RNA
abundance is not matched by increased protein synthesis or
protein abundance (as determined by ribosome profiling or
MS), it is unlikely that the encoded protein contributes to the
ER stress response and therefore the respective locus is not
considered. Similarly, an increase in protein abundance (as
detected by MS), which is not paralleled by an increase in
protein synthesis (as determined by ribosome profiling) most
likely reflects altered protein turnover and therefore the
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respective genes are not considered to be directly regulated by
the UPR.
Among the 267 genes that, according to these criteria, are
induced by ER stress, we identify 37 factors that have previously
been implicated in the UPR pathway. Moreover, we confirm the
induction of numerous ATF4-responsive loci, such as genes that
encode Vascular Endothelial Growth Factor A (VEGFA)36,
Eukaryotic Translation Initiation Factor 4E Binding Protein 1
(EIF4EBP1)37, and several aminoacyl-tRNA synthetases (AARS,
CARS, EPRS, GARS, MARS, SARS, and WARS)38,39. We also
detect the induction of cancer-relevant genes that have been
linked to stress response pathways other than the UPR (such as
the cell cycle regulator and proto-oncogene Polo-like kinase 3,
PLK3), or to inflammation (such as Nuclear Factor Kappa B
Subunit 2, NFKB2, or Prostaglandin-Endoperoxide Synthase 2,
PTGS2)40–42. The majority of proteins that we find induced by
the UPR, however, have not been previously implicated in any
stress response pathway.
Experimental validation of UPR-driven induction of SLFN5.
To validate that these loci are induced by the UPR, we selected
one of the candidates that was upregulated after TM and TH
treatment but for which no connection to a stress response
pathway had been previously reported: Schlafen 5 (SLFN5). The
encoded protein functions as a transcriptional regulator and has
been linked to cancer progression, invasive growth, and patient
survival39,43–46.
To confirm that the induction of SLFN5 is driven by the
UPR, we analyzed mRNA expression after treatment with TM
while simultaneously inhibiting individual branches of the UPR
by pharmacological treatment (Fig. 4a). Efficiency of the
treatments was confirmed by probing for IRE1-mediated
processing of XBP1, PERK-mediated induction of ATF4, and
expression of HSPA5, which is sensitive to inhibition of ATF6.
Inhibition of IRE1 (with STF-083010) or ATF6 (with Cea-
pinA7)47 had no measurable effect on TM-induced accumula-
tion of SLFN5 mRNA in LN-308 and HEK293 cells,
while PERK inhibition (with GSK2606414) completely abol-
ished the effect. Furthermore, induction of SLNF5 mRNA
expression and protein accumulation could be recapitulated by
the expression of a phosphomimetic mutant of EIF2S1 (S51D)
in HEK293 cells but not by expression of the non-
phosphorylatable mutant EIF2S1-S51A (Fig. 4b). Similarly,
transient expression of ATF4 in LN-308 cells (but not of a
control protein) results in accumulation of SLFN5 mRNA
(Fig. 4c). This experimentally confirms induction of SLFN5 by
the UPR through the PERK–EIF2–ATF4 pathway.
Metabolic rewiring by induction of the UPR. In particular
under stress conditions, proliferating cells need to finely coordi-
nate their gene expression, biosynthetic, and bioenergetic pro-
grams to cope with the stress and to allow for anabolic growth
and proliferation. Metabolic reprogramming is a hallmark of
cancer, which e.g. results in an increased conversion of glucose
into lactate (which is known as the Warburg effect). In our data,
we detect upon induction of the UPR an increased expression of
enzymes involved in a metabolic pathway that channels inter-
mediary metabolites from glycolysis to the folate-mediated one-
carbon (1C) metabolism via serine biosynthesis (Fig. 5a). 1C
metabolism has an important role in amino acid homeostasis,
maintenance of epigenetic modifications and the oxidative state
of the cell, and the production of nucleobases (purines and thy-
midylate) that are required for cellular proliferation48,49. There-
fore, it is not surprising that enzymes of the 1C metabolism, in
particular bifunctional methylenetetrahydrofolate dehydrogenase/
cyclohydrolase (MTHFD2), were identified to be among the most
differentially expressed enzymes in cancer50,51. Moreover, the
overexpression of MTHFD2 is associated with proliferation of
tumor cells52 and poor prognosis in breast cancer patients50,53.
Similarly, an increase in serine biosynthetic capacity contributes
to oncogenesis in various tumors and it has been suggested that
phosphoglycerate dehydrogenase (PHGDH), which catalyzes the
first step in serine biosynthesis, is a potential oncogene54–56.
Upon treatment with either TM or TH, we detect upregulation
of the three enzymes that catalyze conversion of 3-
phosphoglycerate into serine (via 3-phospho-hydroxypyruvate
and phosphoserine): phosphoglycerate dehydrogenase (PHGDH),
phosphoserine aminotransferase 1 (PSAT1), and phosphoserine
phosphatase (PSPH). In addition, we observe the induction of
proteins involved in mitochondrial 1C metabolism: serine
hydroxymethyltransferase 2 (SHMT2), bifunctional methylenete-
trahydrofolate dehydrogenase/cyclohydrolase (MTHFD2), and
aldehyde dehydrogenase 1 family member L2 (ALDH1L2). We
also confirmed that SHMT2 and MTHFD2 expression is induced
in a UPR-dependent fashion by demonstrating that the
accumulation of mRNAs encoding these proteins is sensitive to
PERK inhibition and can be mimicked by expression of either a
phosphomimetic version of EIF2S1, or the transcription factor
ATF4 (Fig. 4).
Previously, it has been demonstrated that the expression of all
three enzymes involved in serine biosynthesis (PHGDH, PSAT1,
and SHMT2) and select enzymes of mitochondrial 1C metabo-
lism can be induced by stress response pathways and/or increased
expression of ATF439,56,57. However, induction of the entire
metabolic pathway involved in mitochondrial turnover of folates
has not been reported so far and the possible implications e.g. for
chemotherapeutic treatment have not been assessed.
To indirectly confirm that induction of the UPR increases the
expression of the aforementioned metabolic enzymes, we
analyzed cell growth in conditions where proliferation is limited
by the cells’ ability to synthesize serine. Withdrawal of the non-
essential amino acid serine from the medium impaired cell
growth by ~21%; however, after administration of TM, the effect
was less pronounced (~12% relative to the control) supporting
the hypothesis that induction of the UPR can increase the serine
biosynthetic capacity, partially alleviating growth impairment in
serine-depleted medium (Supplementary Fig. 8).
To understand whether the UPR also increases the metabolic
flux through the mitochondrial 1C metabolism, we analyzed the
redox state of the NADP pool. After induction of the UPR, we
found a significant decrease in the NADP/NADPH ratio
(Fig. 5b). As NADPH can be generated via several different
metabolic pathways including 1C metabolism, we performed a
metabolic labeling experiment to further assess flux of
metabolites through the 1C metabolism adapted from58. We
cultured LN-308 cells in the presence of a stable isotope-labeled
[1,2,3-13C; 2,3,3-2H, 2-15N]serine tracer and analyzed abun-
dance and labeling efficiency of serine, glycine, proline, and
dTTP 24 h after induction of the UPR relative to non-stressed
cells (Fig. 5c–e and Supplementary Fig. 6). As expected, due to
the attenuation of translation, we observed an increase in the
free amino acids serine, glycine and proline after induction of
the UPR. Although serine and proline levels were increased
2.98-fold and 2.78-fold, respectively, the increase in glycine was
much more pronounced (4.34-fold, Fig. 5c). Moreover, while
the fraction of labeled serine was unaffected by the UPR, we
could detect a significant increase in labeled glycine (M+ 4)
produced from labeled serine (M+ 7) by serine hydroxy-
methyltransferase activity (Fig. 5d). This suggests an increased
flux of metabolites through 1C metabolism in LN-308 cells after
TM treatment.
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Fig. 4 SLFN5, SHMT2, and MTHFD2 are induced by the UPR via the PERK–EIF2S1–ATF4 pathway. a Gene expression analysis of SLFN5, SHMT2, and
MTHFD2 mRNAs after activation of the UPR in LN-308 cells. In parallel to stimulation with TM (lanes denoted +), either PERK, IRE1, or ATF6 were
inhibited with small molecules (as indicated at the top). DMSO treatment served as a control. After 6 h, changes to gene expression were monitored. Top
panel: RT-PCR analysis of IRE1-mediated cytoplasmic processing of XBP1 mRNA. Middle panels: Western blotting analyses of BiP (HSPA5), ATF4 and α-
tubulin protein levels. Bottom: analysis of SLFN5 (white bars), SHMT2 (light gray bars) and MTHFD2 (dark gray bars) mRNA abundance by RT-qPCR.
Plotted are mRNA abundance changes (log2 FC) relative to the control treatment and normalized to GAPDH mRNA levels. b Expression analysis of SLFN5,
SHMT2, and MTHFD2 mRNA abundance in HEK293 cells after expression of a phosphomimetic eIF2a protein (lanes S51D), or a non-phosphorylatable
variant (lanes S51A). After 24 h of induction (lanes+ Tet), expression of the mutant proteins is monitored relative to control samples (ctrl). Top panels:
Western blotting analyses with antibodies that recognize either the HA-tag of the stably transfected eIF2a protein-encoding constructs (top panel), total
eIF2α (second panel), S51 phosphorylated eIF2α (third panel), or ATF4. Bottom: analyses of mRNA abundance as described for a. c Expression analysis of
SLFN5, SHMT2, and MTHFD2 mRNA abundance in LN-308 cells after transient expression of ATF4. Western blotting analyses of protein expression using
antibodies specific for the HA-tag of the transfected construct, ATF4, tubulin, or SLFN5. Bottom: RT-qPCR analysis as described for a. Experiments were
performed in at least three biologically independent experiments, representative blots/gels are shown (uncropped images are provided in the
supplementary information). Molecular weight markers (in kDa) or DNA size markers are indicated on the right of each panel. qPCR data are represented
as mean ± SD of three biologically independent experiments measured in technical triplicates (dots represent average values of three technical replicates).
P-values are provided below each bar, n.s. not significant P > 0.05; *P < 0.05, **P < 0.05, ***P < 0.01 as determined by a Student’s t-test (two-sided, true
variance equality, confidence level 0.95, no adjustment for multiple comparisons).
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Fig. 5 The UPR induces rewiring of cellular metabolism. a Schematic depiction of the UPR-induced enzymatic pathway that diverts intermediary
metabolites from glycolysis to fuel mitochondrial one-carbon metabolism via serine biosynthesis. PHGDH: phosphoglycerate dehydrogenase, PSAT1:
phosphoserine aminotransferase 1, PSPH: phosphoserine phosphatase, SHMT2: serine hydroxymethyltransferase 2, MTHFD2: bifunctional
methylenetetrahydrofolate dehydrogenase/cyclohydrolase, ALDH1L2: aldehyde dehydrogenase 1 family member L2, THF: tetrahydrofolate, 5,10-meTHF:
5,10-methylene THF. b Analysis of the redox status of the nicotinamide adenine dinucleotide phosphate pool in LN-308 cells after 24 h of control treatment
with DMSO (yellow bar), or treatment with TM (green bar). P-value: 0.0003. c Analysis of the cellular concentration of the amino acids serine, proline, and
glycine after induction of the UPR (green bars) relative to control treatment with DMSO (yellow bars). Fold-increase values after 24 h of treatment are
displayed at the top of each panel. d Analysis of the isotope distribution of serine and glycine 24 h after application of a metabolically labeled serine tracer.
Cells were either control treated with DMSO (yellow bars) or stimulated for 24 h with TM (green bars). P-values: Serine M+ 7: 0.590, Glycine M+ 4:
0.001. e Analysis of the contribution of mitochondrial folate metabolism to thymidylate synthesis in control-treated LN-308 cells (yellow bars), or after
induction of the UPR with TM (green bars). The isotope distribution of dTTP was analyzed 24 h after administration of a metabolically labeled serine tracer.
P-values: dTTP M+ 0: 0.713, dTTP M+ 2: 0.038, and dTTP M+ 3: 0.002. All data are represented as mean ± SD of three (c–e) or four (b) biologically
independent experiments. A Student’s t-test was used for the statistical testing with the following parameters: two-sided, true variance equality and
confidence level at 0.95. No adjustment for multiple comparisons was made. n.s. not significant P > 0.05, *P < 0.05, ***P < 0.005. Source data are provided
as a Source Data file.
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To assess whether cytosolic or mitochondrial 1C metabolism is
increased, we analyzed the isotope distribution of dTTP after
labeling with the heavy serine tracer. Cytosolic production of
5,10-methylene-THF results in dTTP production with an
increased mass of +3, whereas a mass increases of only +2
Dalton is indicative of metabolization of serine in mitochondria
(Supplementary Fig. 6)58. After induction of the UPR, we observe
a significant increase in M+ 2 dTTP and concomitantly a
decrease in dTTP M+ 3, whereas the background of non-labeled
dTTP remains unchanged (Fig. 5e). This confirms an increased
activity of mitochondrial over cytosolic 1C metabolism.
EIF2S1 phosphorylation induces chemoresistance. Folate
metabolism is the target of antimetabolite drugs that are widely
applied for the treatment of inflammatory diseases and malig-
nancies. To assess whether metabolic rewiring and stimulation of
mitochondrial 1C metabolism changes the response to treatment
with folate-based antimetabolites, we determined upon induction
of the UPR the dose–response curves to several FDA-approved
drugs with different modes of action. Sensitivity to treatment with
the intercalating reagent Doxorubicin and the alkylating com-
pound temozolomide (TMZ) is unchanged after induction of the
UPR (Fig. 6a). Similarly, the half maximal inhibitory concentra-
tion (IC50) of 5-fluoro-uracil, a suicide inhibitor of thymidylate
synthase (TYMS), remains unaffected. In contrast, after the
induction of the UPR, the cells become resistant to treatment with
the folate derivatives methotrexate (MTX) and pemetrexed as
evidenced by an ~10,000-fold increase in IC50 after stimulation
with TM (Fig. 6a). This is not unique to LN-308 cells, as resis-
tance to treatment with MTX after induction of the UPR can also
be observed in the adenocarcinoma-derived cell line A549
(Fig. 6b). Importantly, after expression of a phosphomimetic
EIF2S1 (S51D) mutant protein, resistance to treatment with MTX
can also be observed in HEK293 cells, which in contrast to the
malignantly transformed LN-308 and A549 cell lines are not of
cancerous origin but have been immortalized by transfection of
adenovirus DNA (Fig. 6c).
The central role of EIF2S1 phosphorylation in the UPR-
mediated induction of serine biosynthesis, mitochondrial 1C
metabolism, and resistance to MTX suggests that other stress
kinases that phosphorylate EIF2S1 could similarly induce
resistance to folate-based antimetabolite therapy. This includes,
besides PERK, the kinases general control nonderepressible 2
(GCN2, activated by e.g. amino acid deprivation), protein kinase
R (PKR, activated by double-stranded RNA e.g. upon viral
infection), and heme-regulated inhibitor (HRI, activated upon
oxidative stress, heme deficiency, osmotic shock and heat shock).
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Fig. 6 Stress-mediated phosphorylation of EIF2S1 induces resistance to the folate-based antimetabolites methotrexate and pemetrexed. Survival of
LN-308 cells (a) and A459 cells (b) after 24 h of treatment with the indicated concentrations of the FDA-approved chemotherapeutic reagents in the
absence (black lines, vehicle control) or presence of tunicamycin (red lines). c Survival of stably transfected HEK293 cells before (black lines, vehicle
control) and after induction of expression of a phosphomimetic mutant of EIF2S1 (S51D) (red lines). Cells were treated for 24 h with the indicated
concentrations of FDA-approved chemotherapeutic reagents before scoring survival. d Survival of LN-308 cells in the presence of MTX after activation of
the kinase HRI. Left panel: representative western blots of ATF4 and beta-tubulin protein levels after stimulation with the HRI activator BTdCPU, or the
control compound NCPdCPU. Treatment with DMSO or TM served as control. Right panel: Cell survival in the presence of the indicated concentrations of
MTX of control-treated LN-308 cells (black), TM-treated (red), or BTdCPU-treated LN-308 cells (blue). Data are represented as mean ± SD of three (a, c,
and d) or five (b) biologically independent experiments. Representative western blots of at least three biologically independent replicates are depicted;
pictures of the uncropped membranes are provided in the supplementary information.
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signaling pathway, the integrated stress response (ISR). Signaling
during activation of the ISR is, however, complex and can result
in different cellular responses and cell fate. Moreover, the major
transcription factor downstream of EIF2S1, ATF4, acts in
combination with other proteins that influence its activity and
the cellular outcome of ISR signaling59, among them DDIT3,
ATF3, and TRIB3 that we detect to be upregulated upon
induction of the UPR. We therefore assessed whether MTX
resistance could also be induced upon activation of another ISR
kinase apart from PERK. For this, we treated LN-308 cells with a
small molecule activator of HRI (BTdCPU) or a chemically
related control compound (NCPdCPU)60. As expected, accumu-
lation of ATF4 protein could only be observed after stimulation
with BTdCPU, but not after treatment with the control
compound. Concomitantly, we again detected resistance to
treatment with MTX (Fig. 6d). Moreover, treatment with
Salubrinal, an inhibitor of EIF2S1 phosphatases that impairs
eIF2 function independent of the upstream kinases such as PERK,
induces partial resistance to MTX in LN-308 cells, supporting the
notion that eIF2S1 phosphorylation is a key event to trigger
resistance (Supplementary Fig. 7).
Taken together, this demonstrates that stress-mediated induc-
tion of chemoresistance to folate-based antimetabolites is (a)
driven by phosphorylation of EIF2S1 and (b) appears to be a
resistance mechanism that can be broadly activated in various
different cell types irrespective of malignant transformation.
Resistance to MTX treatment has previously been attributed
mainly to (a) mutation or increased expression of its target
protein dihydrofolate reductase (DHFR), (b) a change in the ratio
of MTX and its polyglutamated form (MTX-PG) mediated by
reduced activity of folylpolyglutamate synthase (FPGS) or an
increase in gamma-glutamyl hydrolase (GGH) activity, or (c)
reduced cellular uptake of MTX or increased efflux mediated by
transporter proteins for xenobiotics61. Several proteins have been
implicated in the transport of MTX, including the solute carrier
family proteins SLC19A1 (aka reduced folate carrier, RFC) and
SLC46A1 (aka proton-coupled folate transporter, PCFT) and the
ATP-binding cassette transporters ABCC1-5 (aka multidrug
resistance-associated proteins 1–5, MRP1-5), ABCG2 (aka breast
cancer resistance protein, BCRP), and ABCB1 (aka multidrug
resistance protein 1, MDR1)62–64. Upon induction of the UPR,
we do not find any of the aforementioned proteins (or related
transporters) to be significantly regulated on the level of
translation or protein abundance (we only detect a small but
significant decrease in RPF abundance for ABCC4 after 2 h but
not 6 h of TM treatment and for ABCC5 and SLC46A1 after 6 h
of TH treatment, see Supplementary Data 3). Also, the levels of
DHFR, FPGS and GGH remain unchanged suggesting that
resistance to MTX is driven by a different and previously
unrecognized pathway.
TYMS is the key enzyme in the sole pathway for de novo
thymidylate production in higher organisms, which is required for
DNA replication and cellular proliferation. Its activity is closely
connected to folate metabolism: to synthesize deoxythymidine
monophosphate (dTMP), TYMS catalyzes reductive methylation of
deoxyuridine monophosphate (dUMP), using a carbon group from
5,10-methylene tetrahydrofolate (5,10-meTHF) and converting it to
dihydrofolate (DHF). Reduction of DHF by DHFR generates
tetrahydrofolate (THF), which can then again participate in the
folate cycle and accept another carbon group. MTX and pemetrexed
inhibit DHFR and block reduction of DHF thus depleting THF. It
remains to be tested whether the UPR-mediated increase in
SHMT2, MTHFD2, and ALDH1L2 allows sustaining of the folate
cycle even under conditions when THF concentrations are
decreased by inhibition of DHFR, resulting in resistance to
treatment with folate-based antimetabolites.
Methods
Cloning. The pcDNA5/FRT/TO vector (ThermoFisher) was modified to contain a
3HA-tag and additional restriction sites, generating pcDNA5/FRT/TO-HA. The
EIF2S1 (NM_004094, [https://www.ncbi.nlm.nih.gov/nuccore/NM_004094.5]) and
ATF4 (NM_001675, [https://www.ncbi.nlm.nih.gov/nuccore/NM_001675]) open
reading frames were amplified by RT-PCR from total RNA extracted from LN-308
cells and, after sequence verification, cloned into the pcDNA5/FRT/TO-HA vector,
generating pcDNA5/FRT/TO-HA-EIF2S1 and –ATF4. PCR-mediated site-directed
mutagenesis was performed to introduce mutations in EIF2S1 that replace the
Ser51 codon (TCC) by codons that either encode aspartic acid (GAC) or alanine
(GCC), generating pcDNA5/FRT/TO-HA-EIF2S1-S51D and –S51A.
Cell culture. Flp-InTM T-RExTM HEK293 (ThermoFisher, RRID:CVCL_U427)
and LN-308 (RRID:CVCL_0394) cells were cultured in DMEM supplemented with
10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C and at 5% CO2.
To induce ER stress, the medium was supplemented with 200 nM Thapsigargin or
2.5 µg/ml Tunicamycin (dissolved in DMSO); DMSO only served as a control. To
inhibit individual branches of the UPR after stimulation with TM, cells were
treated additionally with either 50 µM STF-083010, 1 µM GSK2606414, or 1 µM
CeapinA7. For the activation of HRI, BTdCPU (activator) and NCPdCPU (control
compound) were used at concentrations of 10 µM. Salubrinal was used at a con-
centration of 50 µM to inhibit dephosphorylation of EIF2S1.
Stable Flp-In T-Rex HEK293 cell lines were generated according to the
manufacturer’s instructions (ThermoFisher) using pcDNA5/FRT/TO-HA-EIF2S1-
S51D or –S51A plasmids that encode HA-tagged phosphomimetic (S51D) or non-
phosphorylatable (S51A) eIF2α mutant proteins under the control of an inducible
promoter. For the transfection lipofectamine 2000 (ThermoFisher) was used
according to the manufacturer’s instructions, followed by selection of positive
clones in the presence of 10 µg/ml Blasticidin and 100 µg/ml Hygromycin B. After
induction with 1 µg/ml tetracycline for 24 h, expression of the mutant proteins was
confirmed by immunoblotting.
For the transient expression of ATF4, LN-308 cells were transfected with a
pcDNA5/FRT/TO-HA-ATF4 using lipofectamine 2000 according to the
manufacturer’s instructions.
Immunoblotting. Cells were lysed for 20 min on ice in RIPA buffer (150 mM NaCl,
50 mM Tris pH 8.0, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1×
cOmplete protease inhibitor cocktail (Roche)) followed by clearing of the lysates by
centrifugation at 4 °C for 10 min at 17,000×g. Equal amounts of total protein were
denatured for 5 min at 95 °C in sample buffer (50 mM Tris pH 6.8, 1%SDS, 10%
glycerol, 100 mM DTT, 0.1% bromophenol blue), separated by SDS-PAGE and
transferred onto nitrocellulose membranes (Amersham Protan 0.2 µm NC).
Blocking occurred in TBS-T (10 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween 20)
supplemented with 3% (v/v) BSA or TBS (10 mM TRIS, 150 mM NaCl) supple-
mented with 5 % (v/v) non-fat dry milk powder. The following primary antibodies
were used: anti-BIP (Cell Signaling Technology 3177, RRID:AB_2119845, 1:1000),
anti-IRE1 (Abcam ab96481, RRID:AB_10679929, 1:1000), anti-XBP1 (Biolegend
619501, RRID:AB_315907, 1:500), anti-ATF4 (Cell Signaling Technology 11815,
RRID:AB_2616025, 1:1000), anti-eIF2a (Cell Signaling Technology 5324, RRID:
AB_10692650, 1:1000), anti-eIF2α-pS51 (Abcam ab32157, RRID:AB_732117,
1:2000), anti-alpha-tubulin (Sigma DM1A, RRID:AB_477593, 1:4000), anti-beta-
actin (Sigma A2066, RRID:AB_476693, 1:100), anti-PERK (Cell Signaling Tech-
nology 3192, RRID:AB_2095847, 1:1000), anti-SLFN5 (Sigma HPA017760, RRID:
AB_2189993, 1:1000), and anti-HA (Sigma HA-7, RRID:AB_262051, 1:1000). For
detection either horseradish-peroxidase-coupled antibodies (Peroxidase AffiniPure
Goat Anti-Mouse IgG, Light Chain Specific, or Peroxidase IgG Fraction Mono-
clonal Mouse Anti-Rabbit IgG, Light Chain Specific, Jackson ImmunoResearch,
both 1:10,000) or IRDye-coupled antibodies (Licor #925-32211, RRID:
AB_2651127, #925-68071, RRID:AB_2721181, and #925-68020, RRID:
AB_2687826, all 1:5000) were employed. Detection occurred either by ECL (Clarity
Western ECL Substrate and ChemiDoc Imaging System, BioRad), or with the
Odyssey CLx imaging system (Licor).
RT-PCR analyses. Total cellular RNA was extracted using TRIzol (ThermoFisher)
reagent according to the manufacturer’s instructions. 2.5 µg of RNA were reverse
transcribed in a 20 µl reaction using an oligo-dT primer and SuperScript III
(ThermoFisher) for 1 h at 50 °C. To analyze XBP1 splicing, 25 cycles of PCR were
performed using Phusion High-Fidelity DNA Polymerase (NEB). For quantitative
real-time PCR, per reaction 1 µl of a 1:5 dilution of the RT reaction, 250 nM
primers and SsoFast EvaGreen Supermix (BioRad) were used and analyzed using a
CFX96 Real-Time PCR Detection System (BioRad). All primer-sets were tested for
amplification efficiency and generation of a single product (by melting curve
analysis and gel electrophoresis). Changes to expression levels were calculated
relative to a control gene (GAPDH) according to the mathematical model by
Pfaffl65. Sequences of all primers and additional information are provided in
Supplementary Data 5.
RNA-sequencing library preparation and sequencing. Total RNA was extracted
using TRIzol reagent (ThermoFisher), RNA integrity was checked using the RNA
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Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, Santa
Clara, CA), and concentration was measured with Qubit® RNA Assay Kit in
Qubit® 2.0 Fluorometer (ThermoFisher). Starting with ∼300 ng of total RNA as
input, ribosomal RNA was removed by NEBNext rRNA Depletion Kit (Human/
Mouse/Rat) (New England Biolabs). Subsequently, stranded total RNA-seq
libraries were prepared using the NEBNext® Ultra™ II Directional RNA Library
Prep Kit for Illumina® (New England Biolabs) according to the manufacturer’s
instructions. RNA-seq barcoded libraries that passed the QC step, which was
assessed on the Agilent Bioanalyzer system, were then pooled in equimolar
amounts; 1.8pM solution of this pool were loaded on the Illumina sequencer
NextSeq 500 and sequenced bi-directionally (80 nt read length).
Ribosome profiling. TH- or TM-stimulated cells were treated with 0.1 mg/ml
cycloheximide for 5 min. After washing with ice-cold PBS (supplemented with
cycloheximide), cells were harvested and lysed for 15 min on ice in a buffer con-
taining 5 mM Tris pH 7.4, 1.5 mM KCl, 5 mM MgCl2, 0.5% Triton-X, 0.5% sodium
deoxycholate, 0.1 mg/ml cycloheximide, RNasin and 1× cOmplete protease inhi-
bitor cocktail (Roche). The cell lysate was cleared by centrifugation and digested
with 0.2 U RNaseI (Ambion) per 1 µg RNA for 15 min at 4 °C. To stop the reaction,
1 U SUPERaseIn RNase Inhibitor (ThermoFisher) was added per unit of RNaseI.
Ribosomal complexes were separated on 12 ml 10–50% sucrose gradients (in a
buffer containing 20 mM Tris pH 7.4, 75 mM NaCl, 5 mM MgCl2, 0.1 mg/ml
cycloheximide, and 1 mM DTT) by centrifugation at 4 °C and 35,000 rpm for 3 h in
a SW41 rotor. Fractions were collected at 0.5 ml/min with continuous monitoring
of conductivity and UV absorption at 254 nm. Fractions containing 80S
monosomes were diluted with an equal amount of RNase-free water followed by
organic extraction with Phenol:Chloroform:Isoamylalkohol 25:24:1 (Roth) and
ethanol precipitation. RNAs were then separated by denaturing Urea-PAGE and
visualized by SYBR gold staining. RNAs with a length of 27–33 nt were excised
from the gel and eluted overnight in a buffer containing 300 mM NaOAc pH 5.5, 1
mM EDTA, and 0.25% SDS followed by ethanol precipitation.
After dephosphorylation for 1 h at 37 °C with 20 U of T4 Polynucleotide Kinase
(New England Biolabs), RNAs were ligated to a universal miRNA cloning linker
(New England Biolabs) using truncated T4 RNA ligase 2. After gelpurification
reverse transcription was performed using SuperscriptIII reverse transcriptase
(ThermoFisher) and a primer complementary to the ligated adapter, followed by
alkaline hydrolysis of the RNA strand. The resulting cDNAs were gelpurified and
contaminating sequences originating from rRNA were depleted by substractive
hybridization to a mixture of biotinylated DNA oligonucleotides (for sequences see
Supplementary Data 5) and Streptavidin magnetic beads (New England Biolabs).
The recovered RNAs were then circularized with CircLigase II ssDNA Ligase
(Epicenter) according to the manufacturer’s instructions and subjected to PCR
amplification to generate amplicons suitable for Illumina sequencing. After
gelpurification, DNA concentration was determined using a Qubit Fluorometer
(Qubit 2.0, ThermoFisher Scientific). Bioanalyzer or TapeStation (Agilent) analyses
were performed to assess the quality of the samples followed by deep sequencing on
an Illumina HiSeq platform.
Quantification and statistical analysis of transcriptome. All statistical data
analysis was performed in R66 and Python67. Demultiplexed sequences were sub-
jected to adapter trimmed using trimmomatic68 Version 0.38 and aligned to
GENCODE69 reference annotations for the human genome (GRCh38.pri-
mary_assembly, gencode.v26.annotation) using STAR70 Version 2.5.4b. Gene level
expression were quantified using HTSeq71 and raw RNA-Sequencing count data
normalized and fold changes computed using the DESeq2 library72 with the default
DESeq function that estimated size factors and dispersion, performed negative
binomial GLM fitting and applied Wald statistics for the test of significance of the
comparison treated vs. untreated. Experiments were performed in biological
replicates, except for the treatment with TM where technical replicates were ana-
lyzed (experimental numbers are summarized in the supplemental information).
Ribosome loading scores were computed from ribosomal profiling and RNA-
sequencing data using RiboDiff73. For comparison, log2 transformation was used
for all experimental datasets. The cut-off for differential expression was set at false-
discovery rate of 5%. Differential expression of RNA-Seq and ribosomal profiling
datasets was determined based 95% confidence interval. For RNA-Seq and
ribosomal profiling datasets, only protein-coding regions were considered in
further analysis.
Proteomics sample preparation. Cells were pre-treated with TM or TG as
described above and lysed in 50–200 µl lysis buffer containing 1% SDS, 150 mM
NaCl, 50 mM Tris-HCl (pH 7.8), 1× cOmplete™ (Roche). For each treatment and
each incubation time, three biological replicates were performed. After lysis, 1 µl
Benzonase® Nuclease (Merck KGaA) per 300 µl and an equal volume of 1M
MgCl2 were added to each sample followed by incubation for 30 min at 37 °C. The
cell debris was clarified by centrifugation at 18,000 × g for 30 min and at 4 °C. The
total protein amount was determined using bicinchoninic acid assay (Pierce™ BCA
Protein Assay Kit, ThermoFisher Scientific™). The disulfide bonds were reduced
with 10 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Sigma Aldrich)
at 56 °C for 30 min and free sulfhydryl groups were alkylated with 30 mM
Iodoacetamide (IAA, Sigma Aldrich) for 30 min at 25 °C in the dark. The pro-
teolytic digestion followed a filter-aided sample preparation protocol (FASP) using
a centrifugal device (PALL Nanosep, 30 kDa molecular weight cut-off). The SDS
concentration in cell lysate was reduced to <0.2% by addition of Urea buffer (8M
Urea in 100 mM Tris-HCl pH 8.5) before loading onto the centrifugal device. All
the centrifugation steps were performed at 13,500 × g at 25 °C. The membrane of
the centrifugal device was equilibrated with 100 µl Urea buffer, followed by loading
the sample and subsequently washing three times with 100 µl 50 mM NH4HCO3
(pH 7.8). The enzymatic digestion occurred at 37 °C for a maximum of 15 h using
100 µl digestion buffer containing Trypsin (Trypsin Gold, Promega) at a ratio of
1:25 (w/w, protease to substrate), 0.2 M Guanidine-HCl, 2 mM CaCl2 and 50 mM
NH4HCO3 (pH 7.8). The tryptic peptides were collected by adding 100 µl 25 mM
NH4HCO3 (pH 7.8) and the digestion was stopped by acidifying with 10 µl 10%
trifluoroacetic acid (TFA). The quality of the samples was examined using a
monolithic reverse phase separation method according to Burkhart et al.74. For
further analysis, the peptide solution was stored at −80 °C.
LC–MS/MS analysis. For the separation of peptides, an Ultimate 3000 Rapid
Separation Liquid Chromatography (RSLC, Thermo Scientific) nanoLC system was
used. 1 µg of peptides was loaded for each measurement. The peptides were first
pre-concentrated on a pre-column (Acclaim C18 PepMap100, 100 µm 2 cm,
ThermoFisher Scientific) using 0.1% TFA at a flowrate of 20 µl/min and then
loaded on an analytical main-column (Acclaim C18 PepMap100, 75 µm 50 cm,
Thermo Scientific). A linear gradient employing A: 0.1% formic acid (FA) and B:
84% acetonitrile (ACN), 0.1% FA running from 3 to 35% B in 180 min at a flowrate
of 250 nl/min was used. For the global proteomics analysis, the high resolution
orbitrap mass spectrometer Q Exactive HF (Thermo Scientific) was used in top 15
data-dependent acquisition mode. Full MS scans were acquired at a resolution of
60,000 full width at half maximum (FWHM), AGC target: 1e6 and maximum
injection time of 120 ms. Data-dependent MS/MS scans were acquired on the 15
most abundant ions using a normalized collision energy of 27%, at a resolution of
15,000 FWHM, AGC target: 5e4, isolation width: 1.6m/z, fixed first mass: 120m/z
and dynamic exclusion of 20 s. MS/MS scans were performed only for precursor
ions with charge states between 2 and 4.
Proteomics data analysis. For the data analysis of mass spectrometry data,
Progenesis QI for Proteomics software (version 3.0 NonLinear Dynamics) was
used. X!Tandem75 via SearchGUI interface version 2.5.076 and Mascot 2.4 (Matrix
Science) were used as search algorithm for the peptide identification. For the data
base search, Uniprot human database (downloaded on 22nd of July 2015) was used
with the following search parameters: fixed modification: carbamidomethylation at
cysteine, variable modification: oxidation at methionine, trypsin as protease
(maximum 2 missed cleavages), 10 ppm as MS1 tolerance and 0.02 Da as MS2
tolerance. PeptideShaker version 1.4.077 was used to combine the peptide identi-
fication from X!Tandem and Mascot. Only proteins identified with at least 2
unique peptides were used for further analysis. The statistical data analysis was
performed using R version 3.3.1 (codename “Bug in Your Hair”) using the t.test
function (Student’s t-test, two-sided, true variance equality, confidence level at
0.95). The regulation cut-off was defined as median of the log2-fold-change ± twice
the standard deviation of the log2-fold-change. The significant cut-off was defined
as <0.05. The general calculation, data formatting and illustration of the data was
performed using the R-packages reshape2, dplyr, ggplot2, and gridExtra.
Functional annotation and multi-omics integration. All omics datasets were
integrated via gene name—Uniprot protein id mapping. The datasets were inte-
grated on the biological pathway level by performing GeneOntology—Biological
process analysis on DAVID. All measured data points using corresponding
experimental measurement platform were used as background for pathway ana-
lysis. All data transformations, UPR-related annotations and visualizations were
performed in R 3.4.3.
Analysis of cellular NADPH/NADP+ levels. LN-308 cells were treated for 24 h
with 2.5 nM Tunicamycin (or DMSO as a control) and subsequently washed with
PBS prior to harvesting. For each assay, 4 × 104 cells were resuspended in 50 µl of
PBS and lysed with an equal volume of a solution containing 1% DTAB in 0.2 N
NaOH. NADPH and NADP+ concentrations were determined with the NADP/
NADPH-GloTM assay (Promega) according to the manufacturer’s instructions. In
brief, samples were split into aliquots of 50 µl each and subjected to treated either
with acid (25 μl of 0.4 N HCl to determine NADP+ levels) or base (to determine
NADPH levels). Samples were incubated for 15 min at 60 °C, cooled to room
temperature and neutralized with Tris. 50 µl of each sample were then mixed with
an equal volume of NADP/NADPH-GloTM detection reagent and after incubation
for 45 min subjected to luminescence measurement using a Centro XS3 lumin-
ometer (Berthold).
Labeling with serine and metabolite analyses. Metabolic labeling with a stable
isotope-labeled serine was performed in a setup adapted from Ducker et al.58. In
brief, LN-308 cells were first cultured in MEM (ThermoFisher) supplemented with
10% dialyzed FBS (Sigma Aldrich), 200 µM L-glutamine, and 400 µM L-serine for
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several passages. The cells were then washed twice with PBS before addition of
medium in which the serine had been replaced by 400 µM of stable isotope-labeled,
heavy serine (HO13C2H2-13C2H15NH2-13COOH, Cambridge Isotope Laboratories,
Supplementary Fig. 6). After 24 h the cells were washed twice with PBS, harvested,
snap frozen in liquid nitrogen and stored at −80 °C until further use.
Prior to the extraction of metabolites, each cell pellet was supplemented with
4 µl of an internal standard mixture containing 2.5 mM Serine-m+ 3, 2.5 mM
Glycine-m+ 2, 2.5 mM Proline-m+ 7 (all from Cambridge Isotope Laboratories)
and 0.025 mM dTTP-m+ 12 (Sigma Aldrich). 1 ml of cold 25% MeOH solution
was added to each pellet. Cells were disrupted by three rounds of incubation in
liquid nitrogen for 1 min followed by sonication in a water bath at 4 °C for 10 min.
Proteins were precipitated for 1 h at −80 °C and centrifugation at 18,000×g for
30 min at 4 °C. Equal parts of the supernatant were dried under nitrogen flow
before reconstitution in either 120 µl of 90% ACN (for HILIC-ESI-MS2 analysis) or
in 120 µl of water for the measurement with IC-MS analysis.
The HILIC-ESI-MS analyses were performed on an Ultimate 3000 system
coupled to a Q Exactive HF mass spectrometer (both from Thermo Scientific). The
separation of Serine, Glycine and Proline was carried out on a Zic® HILIC column
(150 × 1mm, 3.5-µm particle size, 100 Å pore size, from Merck Darmstadt). The
mobile phases were 90% acetonitrile (A) and 20 mM ammonium acetate in H2O at
pH = 7.5 (B). The gradient eluted isocratically with 90% ACN for 2.5 min followed
by an increase to 60% over 14 min and held at 60% for 2 min. Subsequent
reconstitution of the starting conditions and re-equilibration with 100% A for
10 min resulted in a total analysis time of 35 min. 4 µl of sample were injected onto
the column and the LC separation was carried out at 25 °C with a flow rate of
100 µl/min. The Q Exactive HF was equipped with a heated electrospray ionization
source (HESI-II, Thermo Scientific) and was operated in positive ion mode. The
source parameters were as follows: sheath gas flow rate: 50; auxiliary gas flow rate:
14; sweep gas flow rate: 3; spray voltage: 4 kV; capillary temperature: 270 °C; S-lens
RF level: 45; probe heater temperature: 380 °C. The data acquisition consisted of
one full MS1 scans (scan range at m/z value of 70–550, resolution at Rm/z 200=
240,000, AGC target value at 3 × 106 ions, maximum IT at 500 ms) followed by
MS2 scans of the most 5 abundant ions (scan range at m/z value of 200–2000,
resolution at Rm/z 200= 30,000, AGC target value at 1 × 105 ions, maximum IT at
54 ms). The chromatographic peak areas at MS1 level were manually integrated in
Skyline. Only identifications with a mass accuracy better than 5 ppm that co-eluted
with the internal standard were considered.
For IC-MS analyses of dTTP, a Dionex ICS 5000 system coupled to a Q Exactive
HF mass spectrometer (both from Thermo Scientific) was used. The separation was
performed on a Dionex IonPac AS11-HC column (2 mm× 250mm, 4 µm particle
size) equipped with a Dionex IonPac AG11-HC guard column (2mm× 250mm,
4 µm particle size) (both from Thermo Scientific) at a flow rate of 380 µl/min. The
temperature of the column compartment was 30 °C. The mobile phase was
deionized water and the gradient was produced by increasing the concentration of
KOH. The gradient started at 10mM KOH for 3min, increased to 50mM in 9min,
from 12 to 17min KOH increased to 100mM and was held at 100mM from 17 to
21min. At 21.1 min KOH concentration was decreased to 10 mM and maintained
4min for re-equilibration. The samples were stored in the autosampler at 8 °C and
4 µl of each sample was injected onto the column. In order to connect the system to
the MS, the high KOH content was removed by exchanging potassium ions against
protons with a Dionex AERS 600, 2 mm anion electrolytic suppressor. The
suppressor current was set to 95mA and the device was operated at 15 °C. Water
was provided to the suppressor by an external pump. The post-column makeup flow
consisting of 100% MeOH, 0.1% FA had a flow rate of 120 µl/min.
The Q Exactive HF was equipped with a heated electrospray ionization source
(HESI-II, Thermo Scientific) and was operated in negative ion mode. The source
parameters were as follows: sheath gas flow rate: 50; auxiliary gas flow rate: 14;
sweep gas flow rate: 3; spray voltage: 2.75 kV; capillary temperature: 230 °C; S-lens
RF level: 45; heater temperature: 380 °C. The data acquisition consisted of one full
MS scans (scan range of m/z value 400–600, at a resolution of Rm/z 200= 240,000,
AGC target value 3 × 106 ions, maximum IT at 500 ms) followed by 4 MS2 scans of
m/z values: 480.982, 482.9916, 483.9979, 493.0096 (resolution at Rm/z 200= 30,000,
AGC target value at 3 × 106 ions, maximum IT at 50 ms, normalized collision
energy at 38 eV).
The chromatographic peak areas at MS1 level were manually integrated in
Skyline. Only identifications with a mass accuracy better than 5 ppm that co-eluted
with the internal standard were considered.
Viability assays. For viability assays, HEK293 cells (1 × 10e4 cells per well) were
grown in poly-D-lysine-coated 96-well plates. LN-308 and A549 cells were grown in
uncoated plates at similar densities. After 24 h of incubation, treatment with the
respective chemotherapeutic drugs at the indicated concentrations occurred. To
elicit the UPR, TM was applied in parallel (conc. 2.5 µg/ml), DMSO only served as
a control. For the activation of HRI, BTdCPU was used, NCPdPU served as a
control (both at a concentration of 10 µM). 50 µM Salubrinal was used to inhibit
PP1-mediated dephosphorylation of EIF2S1. After 24 h of treatment, cell viability
was determined using the CellTiter 96® AQueous One Solution Cell Proliferation
Assay (Promega) according to the manufacturer’s instructions. Survival rates in
presence of the indicated concentrations of the chemotherapeutic reagents were
expressed in % relative to control samples that were treated with DMSO or
TM only.
Data availability
Raw sequencing data are accessible via Gene Expression Omnibus: GEO Series
GSE129757. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE78 partner repository with the dataset
identifier PXD013541 and 10.6019/PXD013541. The source data underlying Figs. 1b–d, 2
and Supplementary Figs. 2, 4 and are provided in the Supplementary Data Files 2 and 3,
the data underlying Fig. 3 and Supplementary Fig. 5 are provided in the Supplementary
Data File 4. The data underlying Fig. 5 and Supplementary Fig. 7 are provided as a Source
Data File. Source data are provided with this paper.
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